Allergy Diagnostics Market size was valued at USD 5.77 billion in 2023. The market is anticipated to grow from USD 6.24 billion in 2024 to USD 13.71 billion by 2032, exhibiting the CAGR of 10.3% during the forecast period.
The allergy diagnostic market is witnessing a significant growth, due to increasing prevalence of allergic diseases. Additionally, the growing emphasis of companies on research and development efforts to create innovative diagnostic products, tests, or kits to address significant unmet medical needs is profoundly influencing the market’s expansion. For instance, in May 2022, Amulet a producer of compact, rapid molecular detection technology introduced Allergy Amulet, a consumer brand featuring a distinctive wearable that notifies individuals of allergens in their food.
To Understand More About this Research:Request a Free Sample Report
Furthermore, global healthcare spending is forecasted to reach USD 10.2 Trillion by 2025, with a considerable portion earmarked for treating chronic diseases like allergies. This indicates a growing readiness to invest in allergy diagnostics, potentially fostering market growth.
Moreover, urban residents face a risk of developing allergic diseases compared to rural residents due to their increased exposure to environmental pollution. The anticipated increase in food allergies is expected to drive market growth. For instance, in May 2024, Dyson launched a new line of air purifiers customized for particularly for urban regions.
Biological Therapies and Digital Health Solutions Drive Allergy Diagnostics Market
Innovation is propelled by advancements in biologic therapies targeting specific immune pathways and the integration of digital health solutions for remote monitoring and management of allergies. These developments are revolutionizing allergy diagnosis and treatment approaches.
For instance, in April 2023, Novartis announced that US FDA has approved for Xolair (omalizumab) to decrease allergic reactions including anaphylaxis, from accidental food exposure in adults and pediatric patients aged 1 year and older with IgE mediated food allergy.
Advancing Allergy Diagnostics Through Patient Centric Care Models
The emphasis on patient-centric care highlights the significance of early diagnosis, proactive management and better patient outcomes in treating allergic reactions. Providers prioritize user-friendly, patient-centric testing solutions to enhance accessibility and compliance with allergy assessments aiming to improve patient outcomes and expand market share.
For instance, LabCorp launched and online portal allowing patients to schedule allergy testing, access results and track allergies, empowering them with health data for proactive allergy management.
Rising Costs of Allergy Diagnostic Instruments
Costs for allergy diagnostic instruments are on the rise owing to the financial challenges for healthcare providers. Cost of high-class instruments like chemistry analyzer, hemodialyzers, chromatography equipment is very high, so return on investment takes longer years to recover. These increased expenses necessitate careful budgeting and resource allocation strategies.
The market is primarily segmented based on product & services, allergen type, test type, end user, and region.
By Product & Services |
By Allergen Type |
By Test Type |
By Region |
|
|
|
|
To Understand the Scope of this Report:Speak to Analyst
Consumables Segment is Expected to Witness the Largest Share During the Forecast Period
The consumables segment held the largest share in the allergy diagnostics market driven by the increasing prevalence of allergies such as inhaled and food allergies. It is also driven by demand for rapid testing to detect allergic disorders.
Meanwhile, the instruments segment including testing platforms is expected to experience significant growth, driven by increasing demand for accurate allergy testing and comprehensive diagnosis and management of allergies. For instance, Metropolis Healthcare Limited (India) launched a new allergy testing platform based on Component Resolved Diagnostics (CRD) for India’s population for easy allergy diagnosis.
Inhaled Allergens Segment Accounted for the Largest Market Share in 2023
The inhaled allergens segment held the largest revenue share. The dominance is driven by the increasing respiratory allergies to the industrialization and air pollution. According to the Allergy and Asthma Foundation of America, seasonal allergic rhinitis affects 81 million Americans, including roughly 26% (67 million) and 19% (14 million) adults and minors respectively, with growth expected, offering future market opportunities. Furthermore, the food allergens are projected to experience the highest growth rate (CAGR) due the rising prevalence of food allergies, particularly in children and demand for accurate and early diagnosis.
In Vitro Test Segment Held The Significant Market Revenue Share in 2023
The in vitro test segment held a significant market share. This is primarily due to its ability in detecting allergen specific IgE. Serum IgE offers superior predictive value for aeroallergen sensitization. According Food Allergy Research and Education’s 2022 statistics, food allergy rates are rising globally, with an estimated 2.8 million Americans projected to have egg allergy and 2.5 million by wheat allergy.
Moreover, the in vivo segment is expected to have fastest growth rate in 2023 attributed to the factors such as rising demand for point-of-care testing and increasing awareness about allergic symptoms. For instance, in June 2023, Alkem Laboratories introduced the “Stop Sneeze to Wheeze” campaign during World Allergy Week 2023 to raise awareness about the co-existence of allergic rhinitis and asthma.
North America Region Registered the Largest Share of the Global Market in 2023
The North America region held the dominant share in 2023. According to the research by the Asthma and Allergy Foundation of America, allergies rank as the 6th most common chronic ailment in U.S., impacting nearly 50 million individuals annually. As medication related fatalities rise, there is a growing demand for swift and precise allergy diagnostics. The prevalence of skin allergies, particularly eczema and skin inflammation among Black Americans along with the high incidence of allergic rhinitis will propel the expansion of allergy diagnostics market in U.S.
The Asia Pacific region is expected for a fastest growth rate in 2023, driven by factors such as healthcare reforms and expanding infrastructure. Increasing population, allergy rates and local company entries further fuel market expansion. Additionally, Japan, China and India are significant markets in this region projected to drive regional market share. Key players in these countries are implementing strategic initiatives to strengthen their market presence. For instance, in October 2022, Siemen’s Healthineers division into two regions (China and the rest of Asia Pacific) to optimize regional potential.
Strategic Partnerships to Drive the Competition
The Allergy Diagnostics market is intensely competitive with market players engaging in strategic collaborations, new product launches, acquisitions, technological innovations, and regional expansion efforts. For instance, in October 2023, Astria Therapeutics, announced a licensing deal with the Inchon’s Science, centering on the OX40 portfolio. The agreement specifically targets the development of STAR-0310 for potential treatments of atopic dermatitis (AD) & immunological disorders.
Some of the major players operating in the global market include:
The Allergy Diagnostics market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product & services, allergen type, test type end user, and their futuristic growth opportunities.
Report Attributes |
Details |
Market size value in 2024 |
USD 6.24 billion |
Revenue forecast in 2032 |
USD 13.71 billion |
CAGR |
10.3% from 2024 – 2032 |
Base year |
2023 |
Historical data |
2019 – 2022 |
Forecast period |
2024 – 2032 |
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
Segments covered |
|
Regional scope |
|
Competitive Landscape |
|
Report Format |
|
Customization |
Report customization as per your requirements with respect to countries, region, and segmentation. |
The key companies in Allergy Diagnostics Market are Astra Biotech GmbH, bioMérieux, Danaher
Allergy Diagnostics Market exhibiting the CAGR of 10.3% during the forecast period.
Allergy Diagnostics Market report covering key segments are product & services, allergen type, test type end user, and region.
The key driving factors in Allergy Diagnostics Market are Biological therapies and digital health solutions drive allergy diagnostics market
Allergy Diagnostics Market Size Worth $ 13.71 Billion By 2032